APL 2

Drug Profile

APL 2

Alternative Names: APL-2

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Ischaemia; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 20 Dec 2016 APL 2 receives Fast Track designation for Paroxysmal nocturnal haemoglobinuria [SC,Injection] (Second-line therapy or greater) in USA
  • 03 Dec 2016 Adverse events, pharmacokinetics and pharmacodynamics data from two phase I trials in Healthy volunteers presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 02 Dec 2016 Interim safety and efficacy data from a phase I trial in Paroxysmal nocturnal hemoglobinuria released by Apellis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top